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Abstract:
Objective To determine whether the presence of
hypercapnia on admission in adult patients admitted
to a university-based hospital in Karachi, Pakistan with
community-acquired pneumonia (CAP) correlates with an
increased length of hospital stay and severity compared
with no hypercapnia on admission.
Study design A prospective observational study.
Settings Tertiary care hospital in Karachi, Pakistan.
Methods Patients who met the inclusion criteria were
enrolled in the study. The severity of pneumonia was
assessed by CURB-65 and PSI scores. An arterial blood
gas analysis was obtained within 24 hours of admission.
Based on arterial PaCO2 levels, patients were divided
into three groups: hypocapnic (PaCO2 <35 mm Hg),
hypercapnic (PaCO2 >45 mm Hg) and normocapnic (PaCO2
<35–45 mm Hg).
Outcomes The primary outcome was the association of
hypercapnia on admission with mean length of hospital
stay. Secondary outcomes were the need for mechanical
ventilation, ICU admission and in-hospital mortality.
Results A total of 295 patients of mean age 60.20±17.0
years (157 (53.22%) men) were enrolled over a 1-year
period. Hypocapnia was found in 181 (61.35%) and
hypercapnia in 57 (19.32%) patients. Hypercapnic patients
had a longer hospital stay (mean 9.27±7.57 days),
increased requirement for non-invasive mechanical
ventilation (NIMV) on admission (n=45 (78.94%)) and
longer mean time to clinical stability (4.39±2.0 days)
compared with the other groups. Overall mortality was
41 (13.89%), but there was no statistically significant
difference in mortality (p=0.35) and ICU admission
(p=0.37) between the three groups. On multivariable
analysis, increased length of hospital stay was associated
with NIMV use, ICU admission, hypercapnia and
normocapnia.
Conclusion Hypercapnia on admission is associated with
severity of CAP, longer time to clinical stability, increased
length of hospital stay and need for NIMV. It should be
considered as an important criterion to label the severity
of the illness and also a determinant of patients who will

Strengths and limitations of the study
►► This is the first study from Pakistan to assess the

association of hypercapnia with increased length of
stay (LOS) and severity in adult patients admitted
with community-acquired pneumonia (CAP) as very
limited data are available from this part of the world.
►► Time to clinical stability and LOS, important
predictors of CAP, were studied in correlation with
PaCO2 levels.
►► This is an observational study from a single centre
with a limited sample size.
►► It is an observational study which may be influenced
by season, time of admission and steroid use.
►► We did not study the underlying cause of death and
complications which developed during hospital stay
in these patients.

require a higher level of hospital care. However, further
validation is required.

Introduction
Severe community-acquired pneumonia
(CAP) is a common infectious condition that
requires hospitalisation. It is a substantial
cause of morbidity and mortality worldwide.1
Limited data are available from Pakistan on
the incidence of CAP, while studies from
the USA and Europe have shown an incidence rate of 1600/100 000 population,
including 250/100 000 requiring hospitalisation.2 Approximately 10–20% of patients
with CAP require intensive care unit (ICU)
admission.3 Mortality may be as high as 58%
if mechanical ventilation and/or ICU admission is needed.4
Most patients with CAP improve within
3 days of hospitalisation with appropriate
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antibiotic therapy. Length of hospital stay (LOS) is
influenced by comorbid conditions, disease severity on
presentation5 and the time required for clinical stability
(TCS). The TCS varies from 3 to 7 days; patients with
more severe CAP on presentation usually require more
days to achieve clinical stability.6 In a study by Menendez
et al7 it was found that hypoxaemia, anaemia, hypoalbuminaemia and other complications appearing within
72 hours of admission were associated with prolonged
hospitalisation. In another study, longer TCS was associated with poor clinical outcomes and ICU stay.8 However,
none of these factors correlated with the PaCO2 levels.
Corticosteroids have been analysed in various CAP
studies and meta-analysis found that the adjunct steroid
therapy in severe CAP reduces the overall LOS but
does not alter in-hospital mortality and length of ICU
stay.9 Prednisolone treatment for 7 days in hospitalised
patients with CAP was found to have shortened TCS
without an increase in complications.10 A short steroid
course decreases the risk of treatment failure and reduces
radiographic progression of pulmonary infiltrates within
3–5 days in severe CAP.11
Patients with severe CAP usually present with acute
respiratory failure, which is the the most common cause
of death in CAP.12 Various prognostic tools have been
used to predict the severity of pneumonia. Hypoxaemic
respiratory failure is a well-known prognostic marker in
different severity of illness scores.12 13 Relatively newer
severity scores, such as SCAP14 and SMART-COP,13have
included low arterial pH as a criterion, but PaCO2 has
not been used as a predictive variable in any such scores.
Hypercapnia is considered an indicator of muscle fatigue
and impending cardiopulmonary arrest. It causes various
physiological effects on the human body, independent of
extracellular and intracellular acidosis.15 16
The aim of this study was to determine whether hypercapnia (defined as a PaCO2 >45 mm Hg on arterial blood
gas (ABG) measurement) on admission has any association with increased LOS and severity in patients with CAP
in comparison with those without hypercapnia on admission.
Methods
Setting
This was an observational prospective study conducted
on patients with a diagnosis of CAP from January to
December 2014 at Aga Khan University Hospital in
Karachi, Pakistan. The hospital ethics review committee
approved the research protocol.
Patients who fulfilled the admission criteria for CAP
as per British Thoracic Society guidelines were admitted
to the study.17 Severity was assessed using the Pneumonia Severity Index (PSI)18 and CURB-65 score at
the time of admission. Inclusion criteria were: (1) age
≥18 years; (2) ABG analysis within 24 hours of admission; (3) fulfilment of CAP diagnostic criteria based on
(a) new infiltrates observed on chest X-ray and/or CT
2

scan chest, (b) one major criterion (axillary temperature >37.8°C, cough or expectoration) or at least two
minor criteria (pleuritic chest pain, dyspnoea, leucocytosis, altered mental status or lung consolidation by
clinical examination). We excluded patients who had
a history of hospitalisation in the previous month or
were transferred from another hospital, patients with
do not resuscitate or comfort care status and those not
meeting the criteria for CAP.
The arterial PaCO2 level was assessed by the Cobas b221
blood gas system (Roche Diagnostics USA) which includes
pH measurement by electrode ion-selective galvanometer
and PaCO2, PaO2 measurement by electrode ion-selective
membrane. ABG analyses were done within 24 hours of
admission. The patients were divided into three groups
based on the level of PaCO2 in the arterial blood: (1)
hypocapnia (PaCO2 level <35 mm Hg); (2) hypercapnia
(PaCO2 >45 mm Hg); and (3) normocapnia (PaCO2 level
35–45 mm Hg).
Non-invasive mechanical ventilation (NIMV) was used
for all those who met one or more eligibility criteria,
experienced acute respiratory distress at rest, had a respiratory rate of >30 breaths/min and/or excessive use of
accessory respiratory muscles or paradoxical abdominal
motion; ABG parameters which included PaO2 <60 mm
Hg while receiving a high level of fraction of inspired
oxygen and/or hypercapnia (PaCO2 >45 mm Hg) with
respiratory acidosis (pH <7.35). The methodology used
was as described in previous literature.19 NIMV was used
in the spontaneous mode with the assistance of pulmonary fellows/residents and trained nurses.
In the majority of patients NIMV was started in the
emergency room but, if the patient was too sick on arrival
or failed a NIMV trial, then intubation was done immediately. Patients were intubated based on the clinical
judgement of the physician and/or based on previously
reported parameters.19 20 NIMV therapy was initiated with
an inspiratory airway pressure of 10 cm H2O and an expiratory airway pressure of 5 cm H2O. This was optimised
using continuous pulse oximetry readings, ABG measurements (at 1 hour and periodically thereafter as clinically
indicated) and patient comfort assessment. The discontinuation of NIMV was based on clinical judgement and
ABG values.
Patients were excluded from NIMV if they had any of
the following: (1) severe haemodynamic instability; (2)
emergency need for cardiopulmonary resuscitation; (3)
home mechanical ventilation; (4) active vomiting; (5)
inability to expectorate; (6) neuromuscular weakness; (7)
contraindications to the use of the mask such as tracheostomy, facial trauma and deformities.
The primary outcome was the association between
hypercapnia on admission and mean LOS; secondary
outcomes were need for mechanical ventilation, ICU
admission and in-hospital mortality. Medical management was similar in all three groups with adherence to
guidelines.17 Oxygen was administered to achieve a level
of arterial oxygen saturation of >90% by pulse oximetry.
Iqbal N, et al. BMJ Open 2017;7:e013924. doi:10.1136/bmjopen-2016-013924
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Data source
We used a non-probability consecutive sampling technique for patient recruitment by assuming LOS is higher
among hypercapnic patients by 35%,21 with a 95% confidence level, 80% power and odds ratio of 1.93, which
required a sample of at least 285 patients.
All patients admitted with CAP who met the inclusion
criteria were included in the study. Informed written
consent was obtained from the patients or the attendant next of kin. Data were collected on each patient’s
demographics, age, sex, comorbid conditions, ABG
values within the first 24 hours of admission, LOS, TCS,
in-hospital mortality, need for NIMV and ICU admission/mechanical ventilation on a predesigned proforma.
Patients were followed till discharge or death, if occurred
during hospitalisation.
Data analysis
All analyses were conducted using the Statistical
Package for Social Science (SPSS) release 18.0, standard
version (1989–02). A descriptive analysis of demographic
features is presented as mean±SD for quantitative
variables (ie, age, LOS and LOS in the hypocapnia, hypercapnia and normocapnia groups) and number (%) for
qualitative variables (ie, gender, mortality, hypocapnia,
hypercapnia and normopcania and mortality in hypocapnia, hypercapnia and normocapnia groups). A χ2 test
was used to compare the mortality in the three groups and
ANOVA was used for mean LOS in the three groups. Due
to the skewed distribution of LOS, it was categorised for
the main analysis. LOS was dichotomised into mean <7
days and >7 days. ORs and their 95% CIs were estimated
using logistic regression with LOS as the outcome variable. Kaplan–Meier plot analysis was done to assess LOS
among the three PaCO2 groups. All significant factors
in the univariate analysis were considered for inclusion
in the multivariable logistic model. All p values were
two-sided and p values ≤0.05 were taken as significant.
Results
A total of 295 patients were enrolled. The mean
age was 60.20±17.0 years, 157 (53.22%) were male
and 138 (46.77%) were female. The majority of the
patients with CAP were hypocapnic (n=181 (61.35%))
while hypercapnia and normocapnia was found in 57
patients (19.32%) in each group. There was no statistically significant difference in age between the groups
(p=0.18). Diabetes (n=25 (43.9%), p=0.03) and chronic
obstructive pulmonary disease (COPD; n=11 (19.3%),
p<0.001) were more common in the hypercapnic group
while patients with normocapnia had ischaemic heart
disease (IHD; n=18 (31.57%), p=0.04). In the hypercapnic
group, 35 patients (61.40%) had pH <7.35 (p<0.001).
There was no statistically significant difference in mean
PaO2 between the three groups (p=0.37).
Hypercapnic patients had a higher CURB-65 score
(3.14±1.28, p=0.004), PSI score (95.68±29.12, p=0.002),
Iqbal N, et al. BMJ Open 2017;7:e013924. doi:10.1136/bmjopen-2016-013924

renal failure (n=42 (73.68%), p=0.01) and bilateral
radiographic infiltrates (n=31 (54.4%), p=0.03) on
presentation compared with the hypocapnic and normocapnic groups. The majority of patients with hypercapnia
received systemic corticosteroids (n=42 (73.7%),
p<0.001), required NIMV (n=50 (87.71%), p=0.03) and
had longer TCS (4.39±2.0, p=0.03) compared with hypocapnic and normocapnic patients (table 1).
Outcome
The mean LOS among patients who survived was 7.4±4.7
days and was statistically significant in the hypercapnic
group (8.9±6.8 days, p=0.04). To investigate the correlation between LOS and TCS in steroid users, a subgroup
analysis was performed. The TCS in steroid users
remained higher in the hypercapnic group (4.43±2.1
mean days, p=0.01), but there was no statistically significant difference in LOS between steroid users in the three
groups (p=0.49; table 2)
Among the three groups, ICU admission/endotracheal intubation was required in 56 (18.98%) patients,
which was not statistically significant (p=0.37). NIMV was
required in 154 (52.20%) patients, of which 45 (78.94%,
p=0.03) were in the hypercapnic group. Overall mortality
was 41 (13.89%) and the difference was not statistically
significant between the groups (p=0.35). The Kaplan–
Meier curve survival analysis of LOS among the three
PaCO2 groups is shown in figure 1.
On univariate analysis, hypercapnia, normocapnia on
admission, in-hospital mortality, IHD, asthma, use of
systemic steroids, PSI score, ICU admission/intubation
and NIMV were significantly associated with increased
LOS. On multivariable analysis, increased LOS in patients
with CAP was associated with NIMV use, ICU admission/intubation, normocapnia and hypercapnia and
was significantly lower in hypocapnic patients (table 3).
Discussion
In this observational study of CAP we found that hypercapnia on presentation is associated with greater severity
of CAP, longer TCS and increased need for NIMV
compared with the other groups. The increased LOS was
associated with hypercapnia and normocapnia compared
with hypocapnia. There was no statistically significant
difference in mortality and intubations/ICU admissions
between the three groups.
LOS consists of two components: TCS and the time
from clinical stability to discharge. This time period
is important as it translates into the cumulative cost of
treatment.22 Interestingly, in our study we found that
hypercapnia leads to longer TCS but, once it is achieved,
the time to discharge is shorter than for the other groups.
This longer TCS is probably due to increased severity
of CAP at the time of presentation. TCS was also longer
in the subgroup of hypercapnic patients who received
adjunct steroids. However, there was no statistically
significant difference in the actual LOS among the three
3
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Table 1 Demographic characteristics of patients admitted with community-acquired pneumonia
Normocapnia (PaCO2
35–45 mm Hg)

Hypocapnia (PaCO2
<35 mm Hg)

Hypercapnia (PaCO2
>45 mm Hg)

57 (19.32%)

181 (61.35%)

57 (19.32%)

61.14±13.85

58.18±18.97

65.77±11.37

0.18

 Men

18 (31.57%)

108 (59.66%)

31 (54.38%)

0.08

 Women

39 (68.42%)

73 (40.33%)

26 (45.61%)

 January to April

24 (42.1%)

53 (29.3%)

34 (59.6%)

 May to August

14 (24.6%)

57 (31.5%)

8 (14%)

 September to December

19 (33.3%)

71 (39.2%)

15 (26.3%)

23 (40.35%)

50 (27.62%)

25 (43.9%)

0.03

IHD

18 (31.57%)

33 (18.23%)

14 (24.6%)

0.04

HTN

27 (47.4%)

68 (37.6%)

27 (47.4%)

0.25

COPD

0

4 (2.2%)

11 (19.3%)

<0.001

Asthma

3 (5.3%)

25 (13.8%)

10 (17.5%)

0.12

5 (8.7%)

8 (4.4%)

35 (61.40%)

<0.001

Total patients
(n=295)
Mean age (years)

p Value

Gender

Season
0.001

Comorbid
Diabetes

pH
 <7.35
 >7.35

52 (91.22%)

173 (95.58%)

22 (38.59%)

PaO2 level (mean)

69.13±17.98

71.68±20.16

78.45±35

PaCO2 level (mean)

37.05±3.65

30.66±9.54

65.36±18.94

<0.001

 <1

36 (63.15%)

59 (32.59%)

15 (26.31%)

0.01

 >1

21 (36.84%)

122 (67.40%)

42 (73.68%)

CURB65 (mean±SD)

2.0±1.06

2.37±1.14

3.14±1.28

0.004

PSI (mean±SD)

66.36±32.4

72.39±29.46

95.68±29.12

0.002

 Unilateral

35 (61.4%)

118 (65.2%)

26 (45.6%)

0.03

 Bilateral

22 (38.6%)

63 (34.8%)

31 (54.4%)

27 (47.4%)

73 (40.3%)

42 (73.7%)

30 (52.6%)

108 (59.7%)

15 (26.3%)

 ER

15 (26.3%)

112 (61.8%)

50 (87.71%)

 SCU

15 (24.5%)

94 (51.93%)

45 (78.94%)

 ICU

0

0

0

 NIMV failure in ER
TCS
(mean±SD), days

0
2.76±2.1

18 (9.9%)
3.17±1.99

5 (8.7%)
4.39±2.0

0.37

Serum creatinine

Chest X-ray infiltrates

Use of steroids
(systemic)
 Yes

<0.001

NIMV therapy
0.03

0.03

COPD, chronic obstructive pulmonary disease; ER, emergency room; HTN, hypertension; IHD, ischaemic heart disease; NIMV, non-invasive
mechanical failure; PSI, pneumonia severity index ; SCU , special care unit TCS, time to clinical stability.

groups of patients who received steroids. We found no
significant impact of systemic steroids on reducing the
overall duration of LOS and TCS, as previously noted.9 10
4

Our results are contrary to those reported in the
studies by Laserna et al21 and Sin et al,23 which both found
that hypocapnia and hypercapnia were associated with
Iqbal N, et al. BMJ Open 2017;7:e013924. doi:10.1136/bmjopen-2016-013924
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Table 2 Outcomes of patients admitted with CAP

Outcomes

Total (n=295)

Normocapnia
Hypocapnia
(PaCO2=35–45 mm Hg) (PaCO2<35 mm Hg)
(n=57)
(n=181)

Hypercapnia (PaCO2>45
mm Hg
(n=57)

P Value

Mortality
Intubation

41 (13.89%)
56 (18.98%)

2 (3.5%)
9 (15.78%)

28 (15.46%)
35 (19.3%)

11 (19.29%)
12 (21.05%)

0.35
0.37

NIMV use

154 (52.20%)

15 (26.31%)

94 (51.93%)

45 (78.94%)

0.03

Overall
LOS (mean), days

7.3±5.0

9.0±5.2

6.24±3.5

9.27±7.57

0.009

LOS (mean) in
survivors, days

7.4±4.7

8.7±5.1

6.7±3.5

8.9±6.8

0.04

LOS in steroid
users who
survived, days
TCS in steroid
users, days

6.3±4.4

6.0±3.5

5.86±2.9

7.57±7.0

0.49

3.0±1.8

1.89±0.6

2.66±1.5

4.43±2.1

0.001

LOS, length of hospital stay; NIMV, non-invasive mechanical ventilation; TCS, time to clinical stability.

increased mortality and ICU admission in patients with
CAP. Moreover, they did not find any difference in LOS
among the three groups. Another study by Yassin et al24
did not find a significant relationship between PaCO2 and
mortality or ICU admission. However, hypercapnia was
associated with longer LOS, which was similar to our study.
We found that hypercapnia correlates well with disease
severity on presentation as suggested by higher CURB-65
and PSI scores in hypercapnic patients compared with
other groups, a finding similar to a previous study.21
Patients with CAP can develop hypercapnia, especially when receiving high concentration oxygen therapy
because of the increase in the physiological dead space, as
observed in COPD.25 26 The severity of the illness itself can
lead to ventilatory failure in CAP. In our study, 38.59% of
patients with hypercapnia had a pH of >7.35, suggesting
chronic hypercapnia. This could be due to unmasking
of underlying COPD in these patients which was undiagnosed until their first presentation to us with CAP.

NIMV is a cost-effective intervention, particularly in
our region where the majority are unable to bear hospital
expenses. The requirement for NIMV in patients with
CAP without any respiratory and cardiac illnesses has
to be decided cautiously. In our study 5.08% of patients
had COPD and most were in the hypercapnic group. In
patients with COPD, Ahmadi et al27 showed that the level
of alveolar ventilation, as reflected by both hypocapnia
and hypercapnia, predicts mortality in oxygen-dependent
COPD patients. However, Aida and colleagues28 found no
association between PaCO2 and mortality in COPD and
found hypercapnia to be a favourable factor in oxygen-dependent COPD. Confalonieri et al29 showed in a subset
analysis that significant benefits of NIMV occurred in
patients with COPD and hypercapnic respiratory failure,
as seen in this study.
Hypercapnia causes various effects on the human
body. A study suggested that, by impairing lung neutrophil function, hypercapnia increases mortality in murine
Pseudomonas pneumonia.15 Hypercapnia inhibits the
expression of interleukin-6, tumour necrosis factor and
Table 3 Multivariable logistic regression model for length of
hospital stay in patients with CAP
IHD
NIMV use

Odds ratio (95% CI)

p Value

0.39 (0.18 to 0.81)
3.48 (1.85 to 6.54)

0.01
<0.001

ICU/intubations

3.96 (1.65 to 9.50)

0.002

Mortality

0.21 (0.08 to 0.56)

0.002

Group

Figure 1 Kaplan–Meier curve showing the length of hospital
stay among the three PaCO2 groups.
Iqbal N, et al. BMJ Open 2017;7:e013924. doi:10.1136/bmjopen-2016-013924

Normal

1.0

<0.001

Hypocapnia
Hypercapnia

0.13 (0.06 to 0.30)
0.55 (0.22 to 1.39)

<0.001
0.20

ICU, intensive care unit; IHD, ischaemic heart disease; LOS, length
of stay >7 days; NIMV, non-invasive mechanical ventilation;.
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phagocytosis in macrophages and causes a defect in resistance to pulmonary infection. This effect was found to be
independent of extracellular and intracellular acidosis.16
In another study it was found that hypercapnia inhibits
autophagy and bacterial killing in human macrophages
by increasing the expression of B-cell lymphoma 2 (Bcl-2)
and B-cell lymphoma-extra large (Bcl-xL), which leads
to immunosuppression and impaired resistance against
bacteria.30 This inhibition was also not attributable to
acidosis.
This is the first study from Pakistan that prospectively
evaluates the association of the PaCO2 level with LOS
and severity, but this study has some limitations: (1) it
is a single-centre study with a small sample size; (2) as
an observational study, there may have been many other
unobserved confounders that could have affected our
results (eg, day and time of admission, seasonality, steroid
use and time to first antibiotic administration); (3) we
did not study the underlying cause of death in these
patients; (4) we did not study the complications developed during the hospital stay; and (5) the decision to use
adjunct steroid therapy was dependent on the treating
physician.

Conclusion
This study suggests that hypercapnia on admission is
associated with severity of CAP, longer TCS, increased
LOS and need for NIMV in patients admitted with
CAP. It should be considered as an important criterion
to label the severity of the illness and also as a determinant of patients who will require a higher level of
hospital care to prevent the aforementioned outcomes.
However, further studies are required for validation of
our results.
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